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Abstract
Atopic dermatitis (AD) is a distressing dermatological disease, which is highly
prevalent during infancy, can persist into later life and requires long-term management
with anti-inflammatory compounds. The introduction of the topical calcineurin
inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major
breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is
approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate
AD. The age restriction was emphasized in a boxed warning added by the FDA in
January 2006, which also highlights the lack of long-term safety data and the
theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been
extensively investigated in short- and long-term studies including over 4000 infants
(<2 yr old). These studies showed that pimecrolimus effectively treats AD in infants,
with sustained improvement with long-term intermittent use. Unlike topical corticos-
teroids, long-term TCI use does not carry the risks of skin atrophy, impaired
epidermal barrier function or enhanced percutaneous absorption, and so is suitable for
AD treatment especially in sensitive skin areas. Most importantly, the studies of
pimecrolimus in infants provided no evidence for systemic immunosuppression, and a
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comprehensive body of evidence from clinical studies, post-marketing surveillance and
epidemiological investigations does not support potential safety concerns. In conclu-
sion, the authors consider that the labelling restrictions regarding the use of
pimecrolimus in infants are no longer justified and recommend that the validity of
the boxed warning for TCIs should be reconsidered.
Atopic dermatitis (AD) is a common skin disease during
infancy and one which imposes a considerable burden on
patients, their families and society. AD is one of the first
diseases encountered during human life with 45% of cases
occurring during the first 6 months. Its clinical presentation in
infants typically involves the face, scalp, trunk and extensor
surfaces of the extremities (1, 2). AD during infancy frequently
persists into later life (3), is often associated with food allergy,
and may be regarded as a presenting sign for the ‘atopic
march’, which leads to the development of other atopic
conditions such as asthma and allergic rhinitis (4, 5). AD is
also associated with a considerable economic burden of up to
$3.8 billion each year in the USA alone (6).
The ultimate goal for the treatment of AD in infants is cure.
Optimally, treatment should be initiated as early as possible to
prevent the inside–outside loss of water (which leads to xerosis,
fissures, pruritus and pain) and the outside–inside penetration
of foreign substances (which leads to irritation and sensitiza-
tion) (7, 8). Recent evidence suggests that normal appearing
non-lesional skin also contains signs of subclinical inflamma-
tion, which treatments should aim to address to induce disease
remission (9). Current AD treatments do not cure the disease,
but instead focus on controlling and reducing its troublesome
signs and symptoms. Given that AD is a chronic disease
requiring treatment for many years or even decades, such
treatments need to be safe and well tolerated.
Topical standard-of-care initial treatment for AD in infants
includes emollients and topical corticosteroids (TCS). TCS are
used on an as-needed basis to treat disease flares and may also
be considered for proactive, intermittent, long-term mainte-
nance treatment of previously affected skin to reduce the
subsequent risk of relapses (9–15). The main drawbacks to TCS
are their potential local and systemic side effects, including skin
atrophy, impaired epidermal barrier function, and percutane-
ous absorption, possibly leading to impaired growth. These
risks are of particular concern with prolonged continuous TCS
use (16–20). Despite TCS being effective AD treatments,
concern about potential side effects has led to widespread
corticosteroid phobia and poor adherence to medication (21–
23). In addition, few TCS have been approved for use in
children under age 2 yr and then for only 3–4 wk.
Two topical calcineurin inhibitors (TCIs), pimecrolimus 1%
cream (Elidel, Meda, Stockholm, Sweden) and tacrolimus
0.03% ointment (Protopic, Astellas, Tokyo, Japan), which
selectively inhibit the synthesis of inflammatory cytokines
released from T-cells and mast cells (24), have been available
for the treatment of AD in patients aged 2 yr and older since
2000–2001. The use of TCIs is currently not approved in
children below 2 yr of age in the USA and Europe, although
pimecrolimus is approved in patients aged 3 months and older
in certain other countries such as Australia and Russia. In
January 2006, the Food and Drug Administration (FDA)
added a boxed warning (‘black box’) to the labels of these TCIs
to emphasize that their long-term safety has not been estab-
lished, to highlight the theoretical risk of skin malignancy and
lymphoma with these treatments and to stress that their use in
infants <2 yr of age is not recommended (25). This black box
represents the first and only time that a warning was issued
based on theoretical rather than proven safety concerns. The
European Medicines Agency (EMA) also advised that TCIs
should be used with caution and limited to second-line use
following a safety review in March 2006.
Eight years after these warnings were issued, it is timely to
re-evaluate the latest clinical efficacy and safety data on TCIs
in infants to assess whether the restrictions regarding their use
and the safety concerns highlighted in the boxed warnings are
still justified. The primary focus of this article is on pimecrol-
imus rather than both TCIs, as only pimecrolimus has been
extensively evaluated in studies including more than 4000
infants. To date, the efficacy and safety of tacrolimus have only
been evaluated in one published open-label study of 50 infants
with AD previously enrolled in a pharmacokinetic investiga-
tion (26, 27). Based on the results of a literature search and on
expert opinion, the authors – a task force of expert paediatri-
cians, dermatologists and allergists – developed consensus
recommendations regarding the use of pimecrolimus in infants
(defined as patients <2 yr of age) and on the safety of TCIs in
general.
Clinical efficacy of pimecrolimus in infants
The favourable clinical efficacy of TCIs in AD is now well
established and documented in several clinical trials. Accord-
ingly, the treatment of AD in infants with pimecrolimus leads
to a substantial reduction in disease flares (28, 29). Further-
more, studies in children and adolescents with AD have shown
that long-term proactive maintenance therapy with TCIs
reduces the risk of subsequent relapses (9, 30–32).
Comprehensive evidence for the clinical efficacy of pime-
crolimus in infants comes from six studies that were conducted
in more than 4000 patients (Table 1). Of note, the Petite study
enrolled the largest population of infants with AD (i.e. 2418
patients) and followed them for the longest period of time ever
studied (i.e. the first 5–6 yr of life). This open-label, parallel-
group study randomized patients to treatment with pimecrol-
imus or TCS and had a ‘real-world’ design in which TCS were
used according to their label and in which those treated with
pimecrolimus were able to briefly use TCS if needed for an
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acute flare (33). The TCS used varied according to the
prescribing practices in different countries and included both
low (e.g. hydrocortisone acetate) and medium potency (e.g.
hydrocortisone butyrate) creams and ointments.
The clinical studies of pimecrolimus in infants have shown
that this TCI leads to a rapid improvement in the signs and
symptoms of AD. In the Petite study, 53% of pimecrolimus-
treated infants had an overall Investigator’s Global Assessment
(IGA) score of 0 or 1 (indicating clear or almost clear of
disease) after 3 wk of treatment (Fig. 1). Similarly, the median
total body surface area (TBSA) affected by AD decreased from
16% at baseline to 4% after 3 wk of pimecrolimus treatment
(33). Other studies in infants have also reported rapid and
significant efficacy benefits with pimecrolimus vs. vehicle such
as reductions in the mean Eczema Area and Severity Index
(EASI) score and improvements in pruritus (28, 34, 35). In
these studies, the majority of the clinical benefit of pimecrol-
imus was observed within 2 wk of treatment. Improvements in
pruritus were even more rapid, occurring within 2 days (35).
Rapid improvements in AD have also been observed in
subgroups of infants included in real-life observational studies
of pimecrolimus (36, 37).
The initial improvement in AD observed in infants treated
with pimecrolimus is sustained over the long term with a
progressive increase in efficacy over time. The Petite study
showed that 89% of pimecrolimus-treated infants had an
overall IGA score of 0 or 1 after 5 yr of as-needed treatment
(Fig. 1) and that the median TBSA affected by AD decreased
to 0% after 1.5 yr (33). Similar short- and long-term disease
improvements were reported for patients treated with TCS in
this study (51% and 92% had an IGA of 0 or 1 after 3 wk and
5 yr, respectively). Moreover, the treatment of AD in infants
with pimecrolimus in the Petite study was associated with a
substantial steroid-sparing effect, with pimecrolimus-treated
patients using TCS for a median of 7 days compared with
178 days in the TCS group over the 5-yr study. This confirms
the reduced steroid requirement observed in previous shorter-
term studies of pimecrolimus (28, 29).
Of particular note, pimecrolimus is effective at treating AD
affecting sensitive skin areas such as the head and neck, which
are common sites of disease presentation in infants. In the
Petite study, 61% of pimecrolimus- and 62% of TCS-treated
infants had a facial IGA score of 0 or 1 after only 3 wk of
treatment, increasing to 97% in both groups at the end of the
5-yr study (33). Similarly, other studies have shown a greater
reduction in the EASI score for the head and neck region with
pimecrolimus vs. vehicle (34, 35).
Table 1 Overview of clinical studies of pimecrolimus in infants
Study Age group Interventions Study design Duration
Petite (33) ≥3–<12 months Pimecrolimus (n = 1205)
TCS (n = 1213)
Open-label, randomized, parallel group 5 yr
Study of the Atopic
March (43)
3–18 months Pimecrolimus (n = 546)
Vehicle (n = 545)
Double-blind, randomized, parallel group
Open-label extension with pimecrolimus
3 yr
Up to 3 yr
Kapp et al. (2002) (28) 3–23 months Pimecrolimus (n = 204)
Vehicle (n = 47)
Double-blind, randomized, parallel group 1 yr
Papp et al. (2005) (29) 3–23 months Pimecrolimus 2 yr (n = 76)
Vehicle 1 yr; pimecrolimus
1 yr (n = 15)
One-year, open-label, non-comparative
extension to Kapp et al. (28)
2 yr
Ho et al. (2003) (34) 3–23 months Pimecrolimus (n = 123)
Vehicle (n = 63)
Six-week randomized, double-blind phase
followed by 20-wk open-label treatment
with pimecrolimus
6 months
Kaufmann et al. (2004) (35) 3–23 months Pimecrolimus (n = 129)
Vehicle (n = 66)
Four-week randomized, double-blind phase
followed by 12-wk open-label treatment with
pimecrolimus and 4-wk follow-up
20 wk
TCS, topical corticosteroids.
Figure 1 Percentage of patients with treatment success in the
Petite study (intent-to-treat population) (33). IGA, Investigator’s
Global Assessment; TCS, topical corticosteroids (low and medium
potency TCS were allowed according to local prescribing practices).
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The effective treatment of AD in infants with pimecrolimus
translates into a beneficial impact on both the quality of life
(QoL) of parents and of affected infants and children (38–40).
This is important as AD has a major negative impact on the
QoL of the affected child and their entire family, with the
impairment in QoL being greater than or equal to that caused
by other common childhood diseases such as asthma (41, 42).
The Study of the Atopic March examined whether early
intervention with pimecrolimus was able to affect the atopic
march in a large population of 1087 infants. The study design
allowed patients to initiate rescue with a mid-potency TCS if
3 days of pimecrolimus led to no improvement. The study did
not show any difference between the pimecrolimus and vehicle
groups in the incidence of asthma, food allergy, allergic rhinitis
and allergic conjunctivitis. However, the discontinuation rate
in this study was unexpectedly high following the implemen-
tation of the FDA boxed warning, and early initiation of TCS
may have obscured any differences between the groups (43).
Clinical safety of pimecrolimus in infants
There is convincing evidence that TCIs have a favourable
safety profile without evidence for severe adverse events (AEs)
(44, 45). Application site reactions, such as burning, erythema
and pruritus, were reported in <1% of infants in a pooled
analysis of data from clinical studies of pimecrolimus in these
patients (46). The most common AEs reported in infants
treated with pimecrolimus were typical childhood infections
and ailments (e.g. nasopharyngitis, pyrexia, upper respiratory
tract infections and bronchitis) with a similar incidence in the
pimecrolimus and control groups, and discontinuations due to
AEs were typically low (<2%) (28, 29, 33–35, 43, 46). An
analysis of safety data from clinical trials and post-marketing
surveillance (PMS) in infants showed no increase in the risk of
systemic infections with pimecrolimus (relative risk vs. vehicle
[95% CI] 1.015 [0.88–1.18]) (47). Similarly, there was no
increased incidence of overall skin infections with pimecroli-
mus in a pooled analysis of data from short-term clinical
studies in infants (relative risk vs. vehicle [95% CI] 1.118 [0.80–
1.61]). The risk of bacterial, fungal, parasitic or viral skin
infections in these studies was also not different in the
pimecrolimus- or vehicle-treated groups (Fig. 2) (46).
The primary purpose of the Petite study was to thoroughly
investigate the safety of pimecrolimus in infants given that
certain infections and disorders were perceived as safety signals
by the FDA on the basis of statistically non-significant
increases in their incidence vs. vehicle control groups in two
previous pivotal studies of pimecrolimus in infants (28, 34, 48).
These differences could be explained by unbalanced random-
ization ratios in the previous studies resulting in substantially
fewer patients in the vehicle groups. In the Petite study, the
crude incidence and relative risk of the infections and disorders
of primary clinical interest as defined by the FDA were not
different in the pimecrolimus and TCS groups (Table 2) (33).
There were also no differences in the time to first occurrence of
these AEs. An additional statistical analysis of AE counts for
frequent events (with a repeated Poisson regression model)
showed that pimecrolimus-treated patients experienced signif-
icantly more events of bronchitis (p = 0.02), infected eczema
(p < 0.001), impetigo (p = 0.045) and nasopharyngitis
(p = 0.04). These increases were not considered clinically
significant as the differences in the incidence of these events
between groups were only 2–4%, and there was no statistical
adjustment for the multiplicity of comparisons (33). Conse-
quently, it was considered that the initial safety concerns from
the FDA were not supported by the Petite study data.
Pharmacokinetic studies of pimecrolimus in infants and
children up to 1 yr in duration demonstrated that there is
minimal systemic exposure following topical application of
this calcineurin inhibitor, even in patients with extensive
disease (49–53). The minimal systemic absorption of topically
applied pimecrolimus is due to its high molecular weight and
lipophilicity (54). In contrast, even short-term topical appli-
cation of hydrocortisone cream 1% (4–106 g) in children can
result in an increase of cortisol plasma levels (55), although
systemic exposure with more recently developed TCS such as
fluticasone propionate is lower (56). The systemic absorption
of TCS is highest on thin delicate skin sites such as the face
where it is 300 times greater than the plantar aspect of the
foot (57).
Importantly, the clinical studies of pimecrolimus in infants
have not revealed any evidence of systemic immunosuppres-
sion. Extensive immunological assessments in the Petite study
showed that pimecrolimus has no effect on the developing
immune system. Neither pimecrolimus nor TCS had an effect
Figure 2 Relative risk for skin infections in infants based on the
incidence density rates (per 1000 patient-months of follow-up) in
pimecrolimus and vehicle groups (46). CI, confidence interval.
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on T-cell or B-cell functions (33). Both the Petite study and a
previous 2-yr study showed that the responses to childhood
vaccinations (e.g. tetanus, diphtheria, measles, varicella and
hepatitis B) were normal in pimecrolimus-treated infants with
AD (33, 58).
A major concern of TCS, in particular when used for long-
term treatment, is their potential to impair the epidermal
barrier function and to cause skin atrophy. This is of special
concern in infants as their epidermis is 20% thinner than that
of adults (59). TCIs do not affect epidermal barrier function or
cause skin atrophy as, unlike TCS, they do not affect fibroblast
function and collagen production (24, 60, 61). A summary of
studies which have compared prolonged use of pimecrolimus
and TCS on the skin barrier is shown in Table 3. In contrast to
TCS, pimecrolimus had no effect on the epidermal structure
and lipid lamellae (19). Both TCS and pimecrolimus improved
stratum corneum integrity and cohesion as well as epidermal
differentiation as measured by expression of filaggrin (19, 20).
Black box safety concerns
A compelling body of evidence now exists which does not
support the safety concerns in the boxed warnings for TCIs.
These warnings state that the long-term safety of TCIs has not
been established and that rare cases of skin malignancy and
lymphoma have been reported in patients using TCIs (48, 62).
The warnings advise against long-term use of TCIs and
emphasize that they are not indicated for use in children
<2 yr of age. The labels also state that an increased risk of
infections, lymphomas and skin malignancies has been
observed following prolonged systemic use of calcineurin
inhibitors in animal studies and in transplant patients after
systemic immunosuppression (48, 62). In addition, the labels
for TCIs highlight that their long-term safety has not been
established beyond 1 yr of non-continuous use (48, 62).
Although ‘long term’ is not specifically defined, the results of
the Petite study have shown that 5 yr of intermittent pime-
crolimus use is not associated with any of the mentioned safety
signals (33).
More than 8 yr after the black box warning was introduced,
there is still no evidence to suggest that TCIs cause skin
malignancies or lymphoma (25). The systemic absorption that
was documented in pharmacokinetic studies of these agents
was far too low to cause a sustained systemic immunosup-
pression, which is required for the development of lymphomas
(27, 49–53, 63, 64). Pre-clinical investigations initially suggested
that exposure to high systemic levels of TCIs – much greater
than can be achieved through topical application of humans –
may result in the development of animal lymphomas (25, 48,
62). One 13-wk study showed that topical application of
pimecrolimus in an ethanolic solution at 47 times the maximum
recommended human dose (based on area under curve
Table 2 Crude incidence and relative risk for AEs of primary clinical
interest during the 5-yr Petite study (safety population) (33)
AE
Crude incidence (%)
Pimecrolimus
(n = 1205)
TCS
(n = 1213) Relative risk (95% CI)
Influenza 6.9 5.7 1.346 (0.90–2.01)
Teething 14.9 14.9 1.179 (0.90–1.54)
Rhinitis 13.9 13.4 1.149 (0.86–1.54)
Nasopharyngitis 59.0 58.9 1.146 (1.01–1.30)
Gastroenteritis 28.2 27.1 1.146 (0.97–1.35)
Otitis media 34.7 31.7 1.135 (0.95–1.35)
Vomiting 22.5 21.3 1.116 (0.91–1.37)
Pyrexia 48.9 49.9 1.104 (0.96–1.26)
Diarrhoea 31.9 31.4 1.081 (0.92–1.27)
Cough 29.9 30.4 1.051 (0.87–1.27)
Pharyngitis 17.8 19.0 0.991 (0.75–1.31)
Hypersensitivity 2.0 1.9 0.989 (0.46–2.13)
Upper respiratory
tract infection
32.0 31.2 0.937 (0.74–1.18)
Eye infection 0.3 0.3 0.871 (0.21–3.53)
Rhinorrhoea 6.8 6.8 0.804 (0.55–1.17)
Wheezing 5.6 5.3 0.752 (0.44–1.29)
Lower respiratory
tract infection
3.7 4.5 0.749 (0.46–1.23)
Viral rash 3.0 4.1 0.719 (0.46–1.12)
AE, adverse event; CI, confidence interval; PIM, pimecrolimus 1%
cream; TCS, topical corticosteroids.
Relative risk based on incidence density rate (pimecrolimus vs. TCS)
and 95% CI was estimated from a Poisson regression model;
incidence density ratio was calculated as 1000*total number of
events/total monitoring time in months.
Table 3 Effect of prolonged use of pimecrolimus and TCS on skin barrier
Property Investigations TCS effect
Pimecrolimus
effect References
Epidermal structure/thickness Optical coherence tomography,
ultrasound and histology
ve Neutral/?+ve Aschoff et al. (2011) (18)
Queille-Roussel et al. (2001) (17)
Lipid bilayers and lipid lamellae Transmission electron microscopy ve Neutral/?+ve Jensen et al. (2009) (19)
Stratum corneum integrity
and cohesion
Transepidermal water loss +ve +ve Jensen et al. (2009) (19)
Epidermal differentiation Expression of filaggrin and loricin +ve +ve Jensen et al. (2009) (19)
Jensen et al. (2012) (20)
Antimicrobial peptide expression Enzyme-linked immunosorbent assay ve ?ve Jensen et al. (2011) (91)
TCS, topical corticosteroids.
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comparisons) resulted in lymphoma in mice (25, 48). However,
the relevance of this animal model to humans is questionable as
mouse skin is much more permeable to molecules of the size of
pimecrolimus than human skin (65). Furthermore, in long-term
carcinogenicity studies, exposure to high doses of TCIs for 2 yr
did not cause any skin cancers in mice and rats (25, 48, 62).
Studies in hairless mice showed that both pimecrolimus and its
vehicle enhanced UV photocarcinogenesis to a similar extent
compared with no topical treatment as did both tacrolimus and
its vehicle, and this forms the basis for the advice in their labels
to avoid or minimize sunlight exposure (48, 62). After
reviewing the available data, the European Dermatology
Forum stated that there is no conclusive evidence to indicate
that long-term topical application of TCIs in humans is
photocarcinogenic (66). Furthermore, the hairless mouse
model is no longer considered useful or recommended for
photosafety testing in guidance from the FDA (67). All actives
and vehicles studied in this model have resulted in an increased
incidence of skin papilloma in rodents.
Prolonged systemic use of calcineurin inhibitors (cyclospor-
ine and tacrolimus) in transplant recipients can lead to
lymphoma and skin cancer due to the immunosuppressive
mode of action of these drugs. The risk of lymphoma is related
to the intensity of immunosuppression and the resulting
inability to control Epstein–Barr virus (EBV) infection (68,
69). An increasing duration and cumulative dose of immuno-
suppressive medication also increases the risk of skin cancer in
organ transplant patients with 40% experiencing skin cancer
within the first 5 yr (70, 71). Estimates suggest that the level of
systemic exposure which leads to lymphoma in organ transplant
recipients is 56- to 108-fold higher than can be achieved
through topical application of calcineurin inhibitors (72).
The rare cases of lymphoma identified in TCI-treated
patients do not have the clinical presentation and histology
that characterize lymphomas due to immunosuppression (64,
73). The typical features of immunosuppression-related lym-
phomas include presentation as nodal or extranodal tumours,
occurrence in unusual locations, polymorphic large cell histol-
ogy, the presence of EBV genome in lymphoma cells, B-cell
lymphomas occurring weeks, months or years after immuno-
modulatory therapy, and spontaneous regression after therapy
is stopped (65, 73). It is possible that the patients identified as
having lymphoma following TCI therapy may actually have
had early forms of cutaneous T-cell lymphoma which were
misdiagnosed as AD (65). Of note, no cases of lymphoma were
reported in the 2418 patients randomized into Petite, although
the study was not powered to specifically address the risk of
malignancies (33).
Five epidemiological studies involving more than 6.5 million
AD patients have not provided any evidence for an increased
lymphoma risk with pimecrolimus (Table 4) (25, 74–77). In the
largest of these studies, which included over 3.5 million AD
patients, no cases of lymphoma were identified in pimecroli-
mus-treated patients (76). There is also no epidemiological
evidence to suggest that TCI use is associated with non-
melanoma or melanoma skin cancer (78). A case–control study
involving a questionnaire mailed to 5000 adults with AD
reported a decreased risk of non-melanoma skin cancer in
patients using TCIs (adjusted odds ratio [95% CI] 0.54 [0.41–
0.69]; Fig. 3) (79). A retrospective observational cohort study
Table 4 Epidemiological studies of the lymphoma risk following exposure to topical pimecrolimus
Study Patients (n) Design Risk of lymphoma with pimecrolimus
Arellano et al. (2007) (74) 293,253 Nested case–control study using
PharMetrics database
No increased risk of lymphoma with pimecrolimus
treatment: adjusted odds ratio 0.8; 95% CI 0.4–1.6
Arana et al. (2011) (25) 625,915 Nested case–control study using
PharMetrics database (extension
of previous)
No increased risk of lymphoma with pimecrolimus
treatment: adjusted odds ratio 0.76; 95%
CI 0.54–1.08
No increased risk of T-cell lymphoma with
pimecrolimus treatment: adjusted odds ratio
0.85; 95% CI 0.25–2.90
Hui et al. (2009) (75) 953,064 Retrospective cohort study using
Kaiser Permante California registries
No increased risk of T-cell lymphoma with
pimecrolimus treatment: adjusted hazard
ratio 2.32; 95% CI 0.89–6.07
Arellano et al. (2009) (76) 3,500,194 Nested case–control study using
United Kingdom-based The Health
Improvement Network database
No cases of lymphoma identified for
pimecrolimus-treated patients
Schneeweiss et al. (2009) (77) 1,200,645 Propensity-score-matched cohort
study using health insurance
claims data
No increased risk of lymphoma with pimecrolimus
compared with untreated patients: rate ratio
1.79; 95% CI 0.92–3.48
No increased risk of lymphoma with pimecrolimus
compared with tacrolimus: rate ratio 1.16; 95%
CI 0.74–1.82
No increased risk of lymphoma with pimecrolimus
compared with TCS: rate ratio 1.15; 95%
CI 0.49–2.72
CI, confidence interval; TCS, topical corticosteroids.
Pediatric Allergy and Immunology 26 (2015) 306–315 ª 2015 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd. 311
Luger et al. Pimecrolimus in infants with AD
of 953,064 AD patients did not show an association between
melanoma and pimecrolimus use (adjusted hazard ratio [95%
CI] 0.69 [0.37–1.28]) (75).
Post-marketing surveillance data and prospective registries
have not identified an increased risk of lymphoma with TCIs
(25). In the latest PMS data for pimecrolimus from 2012 to
2013, only two new cases of lymphoma have been identified
(Meda data on file). In agreement with previous analyses, the
small number of cases of lymphoma is below the expected
background incidence in the population treated (25, 80). One
previous analysis indicated that the incidence of lymphoma in
pimecrolimus-treated patients identified in PMS is 54-fold less
than that in the general population (0.41/100,000 vs. 22.0/
100,000 patient-years of exposure, respectively) (80). Similarly,
the Paediatric Eczema Elective Registry (PEER), which was
initiated in 2004 to follow AD patients aged 2–17 yr treated
with pimecrolimus, has only identified 4 cases of lymphoma
over the past 10 yr. These cases are not the type of lymphoma
that is typically related to immunosuppression.
There is currently no compelling clinical evidence to indicate
that TCIs are associated with an increased risk of infections.
AD patients have a pre-disposition to infections due to
impairment of the skin barrier and cell-mediated immunity
(81). There was no increased risk for overall skin infections in
clinical studies of pimecrolimus in paediatric patients (relative
risk vs. vehicle [95% CI] 0.78 [0.62–1.00]), although there may
be a slightly increased risk for viral skin infections (1.80 [0.98–
3.62]), in particular eczema herpeticum (47). In clinical studies
of pimecrolimus in adult patients, there was no increase in the
risk for overall skin infections (relative risk vs. vehicle [95% CI]
1.3 [0.9–1.8]) or viral skin infections (relative risk vs. vehicle
[95% CI] 1.1 [0.7–2.0]) (44). Similarly, there is no evidence for
an increase in the risk of cutaneous infections with long-term
tacrolimus treatment (82).
Discussion
Currently, there is a paradox in the health care of infants with
AD. The burden of disease is greatest in infants, and early
disease control may prevent AD persistence into later life and
possibly the atopic march to allergic rhinitis and asthma (83).
However, only TCS are currently approved for use in infants.
There is an unmet medical need for safe and effective
alternative therapies for AD in infants, including for appli-
cation on sensitive skin areas such as the face where the
disease commonly presents. Current labelling restrictions in
the USA and Europe, however, prevent the use of TCIs in
infants, despite the wealth of data demonstrating the clinical
benefits and safety in this age group, especially of pimecrol-
imus.
The labelling restrictions for TCIs mean that many infants
with AD who are uncontrolled with or intolerant to TCS have
no treatment alternative. In addition, the long-term safety of
TCS in infants has not been specifically studied and their use is
restricted to 4 wk or less depending on the specific TCS and its
country-specific label (25). In contrast, the long-term safety of
pimecrolimus has been extensively investigated in clinical trials
up to 5 yr in duration (33, 43, 46). This TCI does not cause
skin atrophy and is recognized as an effective treatment for
sensitive skin areas (17, 84). Currently, there are no valid safety
concerns regarding the use of pimecrolimus to justify with-
holding it from infants.
The adverse effects of TCS encourage many parents of
children with AD to use herbal creams. Many of these contain
potent and super potent TCS, allergens and irritants and may
be contaminated with pathogenic bacteria (85, 86). A large
epidemiological study from the USA demonstrated an
increased prevalence of AD in children who were treated with
herbal and other alternative therapies (87). The use of
pimecrolimus would be a much safer alternative to TCS than
herbal topical products.
Since the introduction of the boxed warning for TCIs almost
a decade ago, no compelling evidence has become available to
support a causal link between their use and an increased risk of
lymphoma or skin malignancy. Their safety has been compre-
hensively established through clinical studies, epidemiological
investigations and PMS (25, 33, 43, 44, 74–77). Concerns
regarding an increased risk for cancer after topical use of
calcineurin inhibitors are theoretical only. Indeed, the evidence
available to date indicates that the benefits of TCIs for the
treatment of AD far outweigh any potential or theoretical
risks. The safety of TCI therapy has also been widely
recognized by many professional dermatology and paediatric
organizations (15, 88–90).
The boxed warning for TCIs has had a far-reaching
negative impact on paediatric patients with AD. Although
only based on a theoretical risk, the decision to impose this
warning has resulted in barriers to patient access and
reimbursement for TCIs put in place by insurers and other
payers, and a reluctance of physicians to prescribe TCIs due
to factors such as an increased administrative burden and
fear of litigation. This FDA warning has led to TCIs being
withheld from infants with AD who have the greatest burden
of disease, as well as denying other children and adults with
AD access to effective therapies on the grounds of a
theoretical, but unproven, safety risk. The warning has
generated fear for patients (and their families) who are using
or considering using TCIs. Finally, the black box has had a
negative impact on clinical research programmes for TCIs in
infants and paediatric drug development programmes in AD
in general.
Figure 3 Odds ratio for non-melanoma skin cancer with topical
calcineurin inhibitors (79). Odds ratio adjusted for age, gender, history
of atopic dermatitis and history of non-melanoma skin cancer. CI,
confidence interval.
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Consensus recommendations
Based on the current review of the literature and their clinical
experience, the authors conclude that pimecrolimus cream and,
based on more limited published reports, tacrolimus ointment,
are safe and effective for the treatment of infants at least
3 months of age with AD. The authors consider the current
labelling restrictions regarding TCI use in this population in
Europe and the USA are no longer justified. In particular,
TCIs are suitable for the treatment of sensitive skin areas in
infants such as the face, which is a common site of disease
presentation. Furthermore, based on the extensive evaluations
into the safety of TCIs over the past 8 yr, the authors
recommend that regulatory authorities should remove the
current boxed warnings as this will allow AD patients to have
access to effective medications with comprehensively estab-
lished safety profiles.
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